Teva Swings to Profit on Revenue Growth, Reduced Impairments

TL;DR

**Teva's back in the black, ditching massive impairments and paying down debt – time to buy the turnaround story.**

AI Summary

TEVA PHARMACEUTICAL INDUSTRIES LTD reported a significant turnaround in its financial performance for the three and nine months ended September 30, 2025. Net revenues increased to $4,480 million for the three months, up from $4,332 million in the prior year, and to $12,547 million for the nine months, compared to $12,315 million in 2024. The company swung to a net income of $434 million for the three-month period, a substantial improvement from a net loss of $390 million in the same period last year. For the nine months, net income reached $937 million, reversing a net loss of $1,684 million in 2024. This positive shift was largely driven by the absence of goodwill impairment, which was $600 million in Q3 2024 and $1,000 million for the nine months ended September 30, 2024. Operating income also saw a dramatic improvement, reaching $882 million for the quarter compared to an operating loss of $51 million in Q3 2024. Cash and cash equivalents decreased to $2,203 million as of September 30, 2025, from $3,300 million at December 31, 2024, primarily due to significant debt repayments totaling $4,112 million for the nine-month period. The company's total assets increased slightly to $39,856 million from $39,326 million, while total liabilities decreased to $32,602 million from $33,606 million, indicating an improved balance sheet structure.

Why It Matters

Teva's return to profitability and revenue growth signals a potential turning point for investors, suggesting that past impairments and legal challenges may be stabilizing. The significant reduction in goodwill impairment and legal settlement costs, coupled with increased net revenues, could indicate a healthier operational environment. For employees, this financial stability might reduce restructuring anxieties and foster a more secure work environment. Customers could benefit from a more financially robust Teva, potentially leading to sustained product availability and continued R&D investments. In the broader market, Teva's recovery could impact the competitive landscape, particularly in the generics and biosimilars sectors, as a stronger Teva could exert more pricing pressure and innovation. This positive trend is crucial for Teva to regain market confidence and compete effectively against rivals like Sandoz and Viatris.

Risk Assessment

Risk Level: medium — While Teva reported a net income, its cash and cash equivalents decreased by $1,097 million for the nine months ended September 30, 2025, primarily due to $4,112 million in debt repayments. The company still carries significant senior notes and loans totaling $16,766 million, which could limit future investments or acquisitions. Additionally, the filing mentions ongoing risks from healthcare regulation changes, including the 'One Big Beautiful Bill' (OBBBA) and U.S. Executive Orders in 2025, which could reduce prescription medicine prices and Medicaid enrollment, potentially impacting future revenues.

Analyst Insight

Investors should closely monitor Teva's continued debt reduction efforts and the impact of new healthcare regulations on future revenue streams. While the return to profitability is positive, the substantial debt load and potential pricing pressures warrant a cautious approach. Consider holding existing positions but await further evidence of sustained free cash flow generation and successful navigation of regulatory challenges before increasing exposure.

Financial Highlights

debt To Equity

4.50

revenue

$4,480M

operating Margin

19.7%

total Assets

$39,856M

total Debt

$32,602M

net Income

$434M

eps

$0.38

gross Margin

51.4%

cash Position

$2,203M

revenue Growth

+3.4%

Revenue Breakdown

Key Numbers

• $4.48B — Net revenues (Q3 2025) (Increased from $4.332 billion in Q3 2024)
• $434M — Net income (Q3 2025) (Swung from a net loss of $390 million in Q3 2024)
• $937M — Net income (9 months 2025) (Reversed a net loss of $1,684 million in 9 months 2024)
• $882M — Operating income (Q3 2025) (Improved from an operating loss of $51 million in Q3 2024)
• $600M — Goodwill impairment (Q3 2024) (Zero in Q3 2025, a key driver of profitability turnaround)
• $1.00B — Goodwill impairment (9 months 2024) (Zero in 9 months 2025, significantly boosting net income)
• $2.20B — Cash and cash equivalents (Sept 30, 2025) (Decreased from $3.30 billion at Dec 31, 2024)
• $4.11B — Repayment of senior notes and loans (9 months 2025) (Significant reduction in long-term debt)
• $16.77B — Senior notes and loans (Sept 30, 2025) (Still a substantial amount of long-term debt)
• 1,147,282,512 — Ordinary shares outstanding (Sept 30, 2025) (Reflects the total number of shares outstanding)

Key Players & Entities

• TEVA PHARMACEUTICAL INDUSTRIES LTD (company) — registrant
• New York Stock Exchange (regulator) — exchange where ADS are registered
• U.S. Department of Justice (regulator) — party to Deferred Prosecution Agreement
• IQVIA (company) — provider of market research to the pharmaceutical industry
• Sandoz (company) — competitor
• Viatris (company) — competitor
• Private Securities Litigation Reform Act of 1995 (regulator) — legal framework for forward-looking statements
• Medicaid (regulator) — governmental program affected by OBBBA
• Narcan (company) — generic version provided under opioid settlement
• Israel (person) — country of incorporation

FAQ

Risk Factors

• Debt Repayment and Cash Position [medium — financial]: The company significantly reduced its debt by $4,112 million in the nine months of 2025, leading to a decrease in cash and cash equivalents to $2,203 million from $3,300 million at the end of 2024. While debt reduction is positive, the lower cash balance warrants monitoring.
• Goodwill Impairment Reversal [medium — financial]: The absence of goodwill impairment charges ($600 million in Q3 2024 and $1,000 million for the nine months of 2024) was a primary driver for the reported net income turnaround. This highlights the significant impact of non-cash charges on prior period results.
• Product Pricing and Competition [high — regulatory]: Teva operates in a highly competitive pharmaceutical market, facing pricing pressures and generic competition. Changes in healthcare policies and regulations can impact revenue and profitability.
• Litigation and Legal Proceedings [medium — legal]: The company is involved in various legal proceedings, including those related to product liability and intellectual property. Adverse outcomes could result in significant financial penalties.
• Supply Chain Disruptions [medium — operational]: Global supply chain issues, geopolitical conflicts, and economic instability can affect the sourcing of raw materials, manufacturing, and distribution of Teva's products.

Industry Context

Teva operates in the highly competitive global pharmaceutical industry, with significant pressure from generic drug manufacturers and evolving regulatory landscapes. The industry is characterized by R&D intensity, patent cliffs, and increasing demand for affordable medicines. Companies like Teva must navigate complex pricing negotiations, supply chain challenges, and the constant need for innovation to maintain market share.

Regulatory Implications

Teva faces ongoing regulatory scrutiny regarding drug pricing, manufacturing standards, and marketing practices. Changes in U.S. and international healthcare policies, such as those impacting drug reimbursement or approval processes, can materially affect its financial performance and market access.

What Investors Should Do

1. Monitor debt reduction progress and cash flow generation
2. Analyze the sustainability of profitability improvements
3. Evaluate the impact of ongoing litigation and regulatory developments
4. Assess the performance of key product segments

Key Dates

• 2025-09-30: End of Q3 2025 — Reported significant turnaround in net income and operating income, driven by absence of goodwill impairment.
• 2025-09-30: Nine months ended September 30, 2025 — Net revenues reached $12,547M, and net income was $937M, reversing prior year losses.
• 2024-12-31: End of Fiscal Year 2024 — Reported goodwill impairment of $1,000M for the nine months and $600M for Q3, impacting prior year's net loss.
• 2025-01-01: Start of Fiscal Year 2025 — Company began the year with $3,300M in cash and cash equivalents.

Glossary

Goodwill Impairment

A charge taken when the carrying value of goodwill on a company's balance sheet exceeds its fair value, indicating a loss in value of an acquired business. (The absence of this charge in 2025 was a major factor in Teva's improved net income compared to 2024.)

Accumulated Deficit

The cumulative net losses of a company that have not been offset by net income or other gains. (Teva's accumulated deficit decreased from ($15,173M) to ($14,243M), reflecting the recent profitability.)

Operating Lease Right-of-Use Assets

An asset representing a lessee's right to use an underlying asset for the lease term. (These assets, along with corresponding liabilities, are part of Teva's long-term financial obligations.)

Non-controlling Interests

The portion of equity in a subsidiary that is not attributable to the parent company. (Redeemable non-controlling interests were eliminated in 2025, simplifying the equity structure.)

Senior Notes and Loans

Long-term debt instruments issued by the company, typically with higher priority in repayment than other forms of debt. (Teva has a substantial amount of senior notes and loans ($16,766M as of Sept 30, 2025), which it has been actively repaying.)

Year-Over-Year Comparison

Teva has demonstrated a significant financial recovery compared to the prior year's reporting period. Net revenues saw a modest increase of 3.4% for Q3 2025 and 1.9% for the nine months, but the most striking improvement is in profitability. The company swung from substantial net losses in Q3 2024 ($390M) and the nine-month period ($1,684M) to significant net income ($434M and $937M, respectively), primarily due to the absence of large goodwill impairment charges recorded in 2024. Operating income also dramatically improved, moving from a loss to a profit. While total liabilities decreased, cash reserves have also been drawn down due to substantial debt repayments.

Filing Documents

• d920125d10q.htm (10-Q) — 2491KB
• d920125dex311.htm (EX-31.1) — 10KB
• d920125dex312.htm (EX-31.2) — 10KB
• d920125dex32.htm (EX-32) — 4KB
• 0001193125-25-266895.txt ( ) — 12852KB
• teva-20250930.xsd (EX-101.SCH) — 2146KB
• d920125d10q_htm.xml (XML) — 2609KB

Financial Statements (unaudited)

Financial Statements (unaudited) 5 Item 1.

Financial Statements (unaudited)

Financial Statements (unaudited) 5 Consolidated Balance Sheets 5 Consolidated Statements of Income (loss) 6 Consolidated Statements of Comprehensive Income (loss) 7 Consolidated statements of changes in equity 8 Consolidated Statements of Cash Flows 10

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements 11 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 56 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 83 Item 4.

Controls and Procedures

Controls and Procedures 83 PART II. OTHER INFORMATION 84 Item 1.

Legal Proceedings

Legal Proceedings 84 Item 1A.

Risk Factors

Risk Factors 84 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 84 Item 3. Defaults Upon Senior Securities 84 Item 4. Mine Safety Disclosures 84 Item 5. Other Information 84 Item 6. Exhibits 85

Signatures

Signatures 86 2 Table of Contents TEVA PHARMACEUTICAL INDUSTRIES LIMITED INTRODUCTION AND USE OF CERTAIN TERMS Unless otherwise indicated, all references to the "Company," "we," "our" and "Teva" refer to Teva Pharmaceutical Industries Limited and its subsidiaries, and references to "revenues" refer to net revenues. References to "U.S. dollars," "dollars," "U.S.

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION ITEM1.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS TEVA PHARMACEUTICAL INDUSTRIES LIMITED CONSOLIDATED BALANCE SHEETS (U.S. dollars in millions, except for share data) (Unaudited) September 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 2,203 $ 3,300 Accounts receivables, net of allowance for credit losses of $ 82 million and $ 78 million as of September 30, 2025 and December 31, 2024, respectively 3,810 3,059 Inventories 3,323 3,007 Prepaid expenses 1,115 1,006 Other current assets 477 409 Assets held for sale 1,809 1,771 Total current assets 12,736 12,552 Deferred income taxes 1,634 1,799 Other non-current assets 444 462 Property, plant and equipment, net 4,820 4,581 Operating lease right-of-use assets, net 342 367 Identifiable intangible assets, net 3,936 4,418 Goodwill 15,945 15,147 Total assets $ 39,856 $ 39,326 LIABILITIES AND EQUITY Current liabilities: Short-term debt $ 24 $ 1,781 Sales reserves and allowances 4,134 3,678 Accounts payables 2,355 2,203 Employee-related obligations 561 624 Accrued expenses 2,989 2,792 Other current liabilities 1,103 1,020 Liabilities held for sale 324 698 Total current liabilities 11,491 12,796 Long-term liabilities: Deferred income taxes 399 483 Other taxes and long-term liabilities 3,664 4,028 Senior notes and loans 16,766 16,002 Operating lease liabilities 283 296 Total long-term liabilities 21,111 20,809 Commitments and contingencies , see note 10 Total liabilities 32,602 33,606 Redeemable non-controlling interests — 340 Equity: Teva shareholders' equity: Ordinary shares of NIS 0.10 par value per share; September 30, 2025 and December 31, 2024: authorized 2,495 million shares; issued 1,253 million shares and 1,240 million shares, respectively 58 58 Additional paid-in capital 28,038 27,764 Accumulated deficit ( 14,243 ) ( 15,173 ) Accumulat

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements (Unaudited) Note 1 – Basis of presentation: a. Basis of presentation The accompanying unaudited consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements. In the opinion of management, the financial statements reflect all normal and recurring adjustments necessary for a fair statement of the financial position and results of operations of Teva. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission ("SEC"). The year-end balance sheet data was derived from the audited consolidated financial statements as of December 31, 2024, but not all disclosures required by generally accepted accounting principles in the United States ("U.S. GAAP") are included. In preparing the Company's consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity and disclosure of contingent liabilities and assets at the dates of the financial statements and the reported amounts of revenues and expenses during the reported years. Actual results could differ from those estimates. In preparing the Company's consolidated financial statements, management also considered the economic implications of inflation expectations on its critical and significant accounting estimates. Government actions taken to address macroeconomic developments, as well as their economic impact on Teva's third-party manufacturers and suppliers, customers and markets, could also impact such estimates and may change in future periods. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to determining the valuation and

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements (Unaudited) In July 2025, the FASB issued ASU 2025-05, Financial Instruments - Credit Losses (Topic 326):

View Full Filing

View this 10-Q filing on SEC EDGAR